# Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

> **NCT01855451** · PHASE3 · UNKNOWN · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 189 (actual)

## Conditions studied

- HPV Positive Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cetuximab
- **RADIATION:** RT (70 Gy in 35 fractions)
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01855451
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06-03
- **Primary completion:** 2020-04-30
- **Final completion:** 2023-08-23
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855451, "Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01855451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*